MedPath

Continuous Glucose Monitoring System: Accuracy and Prognostic Value in Critically Ill Patients

Conditions
Critically Ill Patients
Registration Number
NCT07108179
Lead Sponsor
Sinocare
Brief Summary

Whether diabetic or non-diabetic patients, blood glucose management during ICU hospitalization is essential. This study aims to evaluate the accuracy of the iCan Continuous Glucose Monitoring (CGM) System for detecting blood glucose levels in ICU patients, as well as its value in prognostic evaluation, to provide reference for blood glucose management in critically ill patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
120
Inclusion Criteria
  1. Age ≥ 18 years; gender not limited.
  2. Expected ICU (Intensive Care Unit) stay ≥ 48 hours.
  3. Patients requiring frequent blood gas monitoring in the ICU.
Exclusion Criteria
  1. The patient or their family refuses to use CGM for blood glucose monitoring.
  2. Patients with adverse skin conditions (such as rash, active inflammation, etc.) in the device placement area, or those requiring emergency surgical intervention in that area.
  3. Patients who need to undergo computed tomography (CT), X-ray, or magnetic resonance imaging (MRI) scans on the device placement area during the study period.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
AccuracyUp to eight days

"Comparison between arterial blood gas analysis glucose values and CGM values at the same time"

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Continuous glucose monitoring system

🇨🇳

Changsha, changsha, China

Continuous glucose monitoring system
🇨🇳Changsha, changsha, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.